Zoledronic acid 4mg/vial with ampoule of 5ml water for reconstitution: injection.
Ind: Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone. Treatment of hypercalcaemia of malignancy (HCM).
C/I; S/E; Precaution: See above under the text. Dosage & admin: For prevention of skeletalrelated events in patients with advanced malignancies involving bone, the recommended dose is 4mg given as a 15-minute i.v infusion every 3 to 4 weeks. For treatment of HCM, the recommended dose is 4mg given as a single 15-minute i.v
infusion. Patients who show complete response and relapse, or who are refractory to initial treatment may be retreated with zoledronic acid 8mg given as a single 15-minute i.v
infusion. However, at least 1 week must elapse before retreatment to allow for a full response to the initial dose.
No dose adjustment is necessary in patients with mild to moderate renal impairment.
Drug inter: See above under the text.
4mg (5ml) vial x 1 's pack: 26122.00 MRP